Depth of neutrophil nadir after first cycle of R-CHOP predicts outcome in diffuse large B-cell lymphoma – a nationwide population-based cohort study

References

• Elis A, Blickstein D, Manor Y, et al. Association between alopecia and response to chemotherapy in patients with Hodgkin lymphoma. Ther Drug Monit. 2005;27:287–289.
   PubMed Web of Science ®Google Scholar
• Klimm B, Reineke T, Haverkamp H, et al. Role of hematotoxicity and sex in patients with Hodgkin’s lymphoma: an analysis from the German Hodgkin Study Group. J Clin Oncol. 2005;23:8003–8011.
   PubMed Web of Science ®Google Scholar
• Gottlieb JA, Gutterman JU, McCredie KB, et al. Chemotherapy of malignant lymphoma with adriamycin. Cancer Res. 1973;33:3024–3028.
   PubMed Web of Science ®Google Scholar
• García-Suárez J, Flores E, Callejas M, et al. Two-weekly dose-adjusted (DA)-EPOCH-like chemotherapy with high-dose dexamethasone plus rituximab (DA-EDOCH14-R) in poor-prognostic untreated diffuse large B-cell lymphoma. Br J Haematol. 2013;160:510–514.
   PubMed Web of Science ®Google Scholar
• Oki Y, Noorani M, Lin P, et al. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014;166:891–901.
   PubMed Web of Science ®Google Scholar
• Petrich AM, Gandhi M, Jovanovic B, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014;124:2354–2361.
   PubMed Web of Science ®Google Scholar
• Purroy N, Bergua J, Gallur L, et al. Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group. Br J Haematol. 2015;169:188–198.
   PubMed Web of Science ®Google Scholar
• Wilson WH, Sin-Ho J, Pitcher BN, et al. Abstract 469. Phase III randomized study of R-CHOP versus DA-EPOCH-R and molecular analysis of untreated diffuse large B-cell lymphoma: CALGB/alliance 50303. Blood abstracts: 58th annual meeting abstracts. Vol. 128. Washington (DC): American Society of Hematology; 2016.
   Google Scholar
• Wilson WH, Jung SH, Porcu P, et al. A cancer and leukemia group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica. 2012;97:758–765.
   PubMed Web of Science ®Google Scholar
• Wilson WH, Dunleavy K, Pittaluga S, et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol. 2008;26:2717–2724.
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2011;52:e56–93.
   Web of Science ®Google Scholar
• Crawford J, Dale DC, Kuderer NM, et al. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw. 2008;6:109–118.
   PubMedGoogle Scholar
• Pettengell R, Schwenkglenks M. Incidence of neutropenia, chemotherapy delivery, and use of colony-stimulating factor in patients with non-Hodgkin lymphoma of different age groups. Leuk Lymphoma. 2011;52:1133–1136.
   PubMed Web of Science ®Google Scholar
• Zelenetz AD. Risk models for chemotherapy-induced neutropenia in non-Hodgkin’s lymphoma. Oncology (Williston Park). 2003;17:21–26.
   PubMedGoogle Scholar
• Pettengell R, Johnson HE, Lugtenburg PJ, et al. Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma. Support Care Cancer. 2012;20:647–652.
   PubMed Web of Science ®Google Scholar
• Choi YW, Jeong SH, Ahn MS, et al. Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP. J Korean Med Sci. 2014;29:1493–1500.
   PubMed Web of Science ®Google Scholar
• Morrison VA, Weller EA, Habermann TM, et al. Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the intergroup experience (CALGB 9793; ECOG-SWOG 4494). Leuk Lymphoma. 2017;58:1814–1822.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Poniewierski MS, Culakova E. Risk of chemotherapy-induced neutropenic complications when treating patients with non-Hodgkin lymphoma. Expert Opin Drug Saf. 2016;15:483–492.
   PubMed Web of Science ®Google Scholar
• Arboe B, Josefsson P, Jørgensen J, et al. Danish national lymphoma registry. Clin Epidemiol. 2016;8:577–581.
   PubMed Web of Science ®Google Scholar
• Arboe B, El-Galaly TC, Clausen MR, et al. The Danish national lymphoma registry: coverage and data quality. PLoS One. 2016;11:e0157999.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383.
   PubMedGoogle Scholar
• Schmidt M, Schmidt SAJ, Sandegaard JL, et al. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol 2015;7:449.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced international prognostic index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123:837–842.
   PubMed Web of Science ®Google Scholar
• Shipp H, A, Anderson JR, Harrington DP, et al. A predictive model for aggressive non-Hodgkin’s lymphoma. The international non-Hodgkin’s lymphoma prognostic factors project. N Engl J Med. 1993;329:987–994.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481.
   Web of Science ®Google Scholar
• Cox D. Regression models and life tables. J Royal Stat Soc B. 1972;34:187–220.
   Web of Science ®Google Scholar
• Brosteanu O, Hasenclever D, Loeffler M, et al. Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin’s disease. Ann Hematol. 2004;83:176–182.
   PubMed Web of Science ®Google Scholar
• Di Maio M, Gridelli C, Gallo C, et al. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol. 2005;6:669–677.
   PubMed Web of Science ®Google Scholar